Interestingly, when this setting was used, greater anti-tumor activity was observed for the Fc-LS variants tested in hFcRn/Rag1−/− tumor xenografted mice, showing a positive correlation between FcRn-binding enhancement and in vivo efficacy (18). The gene discussed is FCGRT; the disease is neoplasm.